These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 22547412)

  • 41. Benign or not benign MS: a role for routine neuropsychological assessment?
    Benedict RH; Fazekas F
    Neurology; 2009 Aug; 73(7):494-5. PubMed ID: 19641172
    [No Abstract]   [Full Text] [Related]  

  • 42. Chronic cerebrospinal venous insufficiency and iron deposition on susceptibility-weighted imaging in patients with multiple sclerosis: a pilot case-control study.
    Zivadinov R; Schirda C; Dwyer MG; Haacke ME; Weinstock-Guttman B; Menegatti E; Heininen-Brown M; Magnano C; Malagoni AM; Wack DS; Hojnacki D; Kennedy C; Carl E; Bergsland N; Hussein S; Poloni G; Bartolomei I; Salvi F; Zamboni P
    Int Angiol; 2010 Apr; 29(2):158-75. PubMed ID: 20351672
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?
    Tintoré M; Rovira A; Río J; Tur C; Pelayo R; Nos C; Téllez N; Perkal H; Comabella M; Sastre-Garriga J; Montalban X
    Neurology; 2008 Mar; 70(13 Pt 2):1079-83. PubMed ID: 17881717
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Parallels between clinical aspects and MRI in multiple sclerosis].
    Grimaud J; Pageot N; Rovaris M
    Rev Neurol (Paris); 2001 Sep; 157(8-9 Pt 1):884-90. PubMed ID: 11677412
    [No Abstract]   [Full Text] [Related]  

  • 45. Predictive role of evoked potential examinations in patients with clinically isolated optic neuritis in light of the revised McDonald criteria.
    Simó M; Barsi P; Arányi Z
    Mult Scler; 2008 May; 14(4):472-8. PubMed ID: 18208873
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Diffusely abnormal white matter in chronic multiple sclerosis: imaging and histopathologic analysis.
    Seewann A; Vrenken H; van der Valk P; Blezer EL; Knol DL; Castelijns JA; Polman CH; Pouwels PJ; Barkhof F; Geurts JJ
    Arch Neurol; 2009 May; 66(5):601-9. PubMed ID: 19433660
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Measurement of brain and spinal cord atrophy by magnetic resonance imaging as a tool to monitor multiple sclerosis.
    Bakshi R; Dandamudi VS; Neema M; De C; Bermel RA
    J Neuroimaging; 2005; 15(4 Suppl):30S-45S. PubMed ID: 16385017
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evoked potentials are of little use in the diagnosis or monitoring of MS: yes.
    McGuigan C
    Mult Scler; 2013 Dec; 19(14):1820-1. PubMed ID: 24277732
    [No Abstract]   [Full Text] [Related]  

  • 49. The telltale scan: APOE epsilon4 in multiple sclerosis.
    Masterman T; Hillert J
    Lancet Neurol; 2004 Jun; 3(6):331. PubMed ID: 15157846
    [No Abstract]   [Full Text] [Related]  

  • 50. Optical coherence tomography should be part of the routine monitoring of patients with multiple sclerosis: yes.
    Saidha S; Calabresi PA
    Mult Scler; 2014 Sep; 20(10):1296-8. PubMed ID: 25160122
    [No Abstract]   [Full Text] [Related]  

  • 51. What you cannot get from routine MRI of MS patient and why - The growing need for atrophy assessment and seeing beyond the plaque.
    Hartel M; Kluczewska E; Pierzchała K; Adamczyk-Sowa M; Karpe J
    Neurol Neurochir Pol; 2016; 50(2):123-30. PubMed ID: 26969569
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Natural history of multiple sclerosis: early prognostic factors.
    Mowry EM
    Neurol Clin; 2011 May; 29(2):279-92. PubMed ID: 21439441
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Optical coherence tomography should be part of the routine monitoring of patients with multiple sclerosis: no.
    Jenkins TM; Toosy AT
    Mult Scler; 2014 Sep; 20(10):1299-301. PubMed ID: 25160123
    [No Abstract]   [Full Text] [Related]  

  • 54. Brain atrophy measurements should be used to guide therapy monitoring in MS - YES.
    Zivadinov R; Dwyer MG; Bergsland N
    Mult Scler; 2016 Oct; 22(12):1522-1524. PubMed ID: 27335098
    [No Abstract]   [Full Text] [Related]  

  • 55. Preventing brain atrophy should be the gold standard of effective therapy in MS (after the first year of treatment): Yes.
    Rudick RA; Fisher E
    Mult Scler; 2013 Jul; 19(8):1003-4. PubMed ID: 23818018
    [No Abstract]   [Full Text] [Related]  

  • 56. Multiple sclerosis: Lesion location may predict disability in multiple sclerosis.
    Sastre-Garriga J; Tintoré M
    Nat Rev Neurol; 2010 Dec; 6(12):648-9. PubMed ID: 21131911
    [TBL] [Abstract][Full Text] [Related]  

  • 57. MRI: measure of efficacy.
    Ebers G
    Brain; 2000 Nov; 123 ( Pt 11)():2187-8. PubMed ID: 11050019
    [No Abstract]   [Full Text] [Related]  

  • 58. Functional MRI in multiple sclerosis: a simple motor task gives insights into a complex disease.
    Enzinger C; Fazekas F
    Lancet Neurol; 2005 Oct; 4(10):589-90. PubMed ID: 16168924
    [No Abstract]   [Full Text] [Related]  

  • 59. MRI-clinical correlations: more than inflammation alone-what can MRI contribute to improve the understanding of pathological processes in MS?
    Wayne Moore GR
    J Neurol Sci; 2003 Feb; 206(2):175-9. PubMed ID: 12559507
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cortical lesion counts by double inversion recovery should be part of the MRI monitoring process for all MS patients: yes.
    Calabrese M; De Stefano N
    Mult Scler; 2014 Apr; 20(5):537-8. PubMed ID: 24692503
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.